On April 22, 2021 Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, reported that it will host its virtual R&D Day for analysts and investors at 10:00 a.m. – 1:00 p.m. ET on Wednesday, April 28, 2021 (Press release, Trillium Therapeutics, APR 22, 2021, View Source [SID1234578359]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The R&D Day agenda will include:

·a clinical update for TTI-622 and TTI-621,
·new strategic priorities in terms of target indications and drug combinations across hematologic malignancies and solid tumors, and
·updated milestones and guidance for 2021.

More information on Trillium’s R&D Day will be available at: ir.trilliumtherapeutics.com/events-and-presentations/RD-Day

You can join the webcast at: View Source

On April 22, 2021 Synthekine Inc., an engineered cytokine therapeutics company, reported a new agreement with Stanford University to license cytokine partial agonist programs for IL-10, IL-12 and IL-22 (Press release, Synthekine, APR 22, 2021, View Source [SID1234578375]). These programs augment a growing pipeline of selective cytokine partial agonists at Synthekine that is maturing toward clinical development.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Most cytokines are pleiotropic and drive a range of signaling responses across multiple cell types, which limits their potential as therapeutics. Research conducted in the laboratory of Chris Garcia, PhD, a Howard Hughes Medical Institute Investigator and professor of structural biology at Stanford, has shown that IL-10, IL-12, and IL-22 can be tuned to achieve specific signaling. Modifying these cytokines enables selective activity to be directed to specific cell types for therapeutic benefit, often by decoupling efficacy from toxic effects driven by non-specific immune system activation. Synthekine plans to leverage discoveries in IL-12, recently published in the journal Cell, to develop potential treatments for cancer, and the discoveries in IL-10, recently published in the journal Science, and IL-22, recently published in the journal Immunity, to develop potential treatments for autoimmune disease.

"Synthekine was founded two years ago with several cytokine partial agonist programs based on the work from the Garcia Laboratory, and we have already moved two of those programs into IND enabling development," said Debanjan Ray, CEO of Synthekine. "Extending our license with Stanford allows us to bring in three new promising cytokine partial agonist programs that we believe have considerable potential in treating cancer and autoimmune disease."

On April 22, 2021 BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) reported that the company will report its first quarter 2021 financial results on Thursday, May 6, 2021 (Press release, BioCryst Pharmaceuticals, APR 22, 2021, View Source [SID1234578360]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 877-303-8027 for domestic callers and 760-536-5165 for international callers and using conference ID # 2660434. A live webcast of the call and any slides will be available online at the investors section of the company website at www.biocryst.com. A telephone replay of the call will be available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference ID # 2660434.

On April 22, 2021 Virpax Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), reported that the Company has engaged Torreya Capital, LLC (Torreya) to serve as the exclusive financial advisor for the Company’s partnering and licensing efforts in strategic global markets (Press release, Virpax Pharmaceuticals, APR 22, 2021, View Source [SID1234578376]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Torreya is a global investment bank that has facilitated more than $100 billion worth of transactions in the life sciences industry since its inception in 2007.

"We are excited to be working with Torreya to expand our partnerships in key markets," stated Anthony Mack, Chairman and CEO of Virpax Pharmaceuticals. "There is a growing global demand for non-opoid, non-addictive pain treatments and we believe that our product candidates, Epoladerm, Probudur, and Envelta can offer a competitive advantage in their addressable markets," concluded Mr. Mack.

"We look forward to helping Virpax Pharmaceuticals find strong regional partners for their innovative acute and chronic pain product candidate pipeline," said Tom Bird, Partner of Torreya. "Virpax’s product candidates incorporate its proprietary technologies that may enable the product candidates to deliver enhanced benefits with non-addictive pain relief."

On April 22, 2021 EDAP TMS S.A. (NASDAQ: EDAP) (the "Company"), a global leader in robotic energy-based therapies, reported the launch of a follow-on public offering of its American Depositary Shares, or ADSs, each representing one ordinary share of the Company (Press release, EDAP TMS, APR 22, 2021, View Source,ordinary%20share%20of%20the%20Company. [SID1234578410]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Piper Sandler is acting as the sole book-running manager for the offering.

A shelf registration statement on Form F-3 (including a prospectus) relating to the Company’s American Depositary Shares was filed with the Securities and Exchange Commission (the "SEC") and has become effective. The Company has also filed a preliminary prospectus supplement with respect to the proposed offering. Before purchasing ADSs in the offering, you should read the preliminary prospectus supplement and the accompanying prospectus, together with the documents incorporated by reference therein. You may obtain these documents for free by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, a copy of the preliminary prospectus supplement (and accompanying prospectus) relating to the offering may be obtained from Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, Attention: Prospectus Department, by telephone at (800) 747-3924 or by email at [email protected].

The Company also announced that it expects to report that total revenues were between €10.0 million and €10.4 million for the three months ended March 31, 2021, primarily driven by strength in its Distribution division, as compared to €7.6 million for the same period in 2020, with the Company’s gross margin expected to be between 40% and 44% for the period, as compared to 40.2% gross margin for the same period in 2020. The Company also expects to report that its cash and cash equivalents were approximately €24.4 million as of March 31, 2021.

In this press release, the Company has presented preliminary estimates of certain unaudited financial information for the three months ended March 31, 2021. The Company has provided ranges, rather than specific amounts, for the preliminary estimates of the unaudited financial information primarily because its financial closing procedures for the three months ended March 31, 2021 are not yet complete and, as a result, its final results upon completion of its closing procedures may vary materially from the preliminary estimates. The preliminary results are not a comprehensive statement of the Company’s financial results for this period. In addition, even if the Company’s actual results are consistent with these preliminary results, those results or developments may not be indicative of results or developments in subsequent periods. The preliminary estimates for the three months ended March 31, 2021 presented in this press release have been prepared by, and are the responsibility of, management. KPMG S.A., the Company’s independent registered public accounting firm, has not audited, reviewed, compiled or performed any procedures with respect to such preliminary data. Accordingly, KPMG S.A. does not express an opinion or any other form of assurance with respect thereto, and you should not place undue reliance upon these preliminary estimates.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. In particular, no public offering of the ADSs will be made in Europe.